Cabergoline

Cabergoline

Systematic (IUPAC) name
N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]- 6-(2-propenyl)-8g-ergoline-8-carboxamide or 1-[(6-allylergolin8β-yl)- carbonyl]-1- [3-(dimethylamino)propyl]-3-ethylurea
Clinical data
AHFS/Drugs.com	monograph
Licence data	US FDA:link
Pregnancy cat.	B(US)
Legal status	℞-only (US)
Routes	Oral
Pharmacokinetic data
Bioavailability	First-pass effect seen; absolute bioavailability unknown
Protein binding	Moderately bound (40% to 42%); concentration- independent
Metabolism	Hepatic, predominately via hydrolysis of the acylurea bond or the urea moiety
Half-life	63-69 hours (estimated)
Excretion	Urine (22%), feces (60%)
Identifiers
CAS number	81409-90-7 Y
ATC code	G02CB03 N04BC06
PubChem	CID 54746
IUPHAR ligand	37
DrugBank	APRD00836
ChemSpider	49452 Y
UNII	LL60K9J05T Y
KEGG	D00987 Y
ChEBI	CHEBI:3286 Y
ChEMBL	CHEMBL1201087 N
Chemical data
Formula	C26H37N5O2
Mol. mass	451.604 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 Y Key:KORNTPPJEAJQIU-KJXAQDMKSA-N Y
N(what is this?)  (verify)

Cabergoline (brand names Dostinex and Cabaser), an ergot derivative, is a potent dopamine receptor agonist on D2 receptors. In vitro, rat studies show cabergoline has a direct inhibitory effect on pituitary lactotroph (prolactin) cells.^[1] It is frequently used as a first-line agent in the management of prolactinomas due to higher affinity for D2 receptor sites, less severe side effects, and more convenient dosing schedule than the older bromocriptine.

History

Cabergoline was invented by scientists working for the Italian drug company Farmitalia-Carlo Erba SpA in Milan in 1981/82^[2], who were experimenting with semisynthetic derivatives of the ergot alkaloids. Farmitalia-Carlo Erba was acquired by Pharmacia in 1992, which in turn was acquired by Pfizer in 2002. The drug was approved by the FDA on December 23, 1996. It went generic in late 2005 following US patent expiration.

Intellectual property

Farmitalia filed a patent application for Cabergoline in 1982, and U.S. Patent 4,526,892 issued in July 1985.

Pharmacology

Although cabergoline is commonly described principally as a dopamine D₂ receptor agonist, it also possesses significant affinity for the D₃, D₄, 5-HT_1A, 5-HT_2A, 5-HT_2B, 5-HT_2C, α_2B- receptors, and moderate/low affinity for the D₁ and 5-HT₇ receptors. Cabergoline functions as an agonist at all receptors except for 5-HT₇ and α_2B-, where it acts as an antagonist.^[3]

Pharmacokinetics

Following a single oral dose, resorption of cabergoline from the gastrointestinal (GI) tract is highly variable, typically occurring within 0.5 to 4 hours. Ingestion with food does not alter its absorption rate. Human bioavailability has not been determined since the drug is intended for oral use only. In mice and rats the absolute bioavailability has been determined to be 30 and 63 percent, respectively. Cabergoline is rapidly and extensively metabolized in the liver and excreted in bile and to a lesser extent in urine. All metabolites are less active than the parental drug or inactive altogether. The human elimination half-life is estimated to be 63 to 68 hours in patients with Parkinson's disease and 79 to 115 hours in patients with pituitary tumors. Average elimination half-life is 80h.

The therapeutic effect in treatment of hyperprolactinemia will typically persist for at least 4 weeks after cessation of treatment.

Mechanism of action

Cabergoline is a long-acting dopamine D2-receptor agonist and in vitro rat studies show a direct inhibitory effect on the prolactin secretion in the pituitary's lactotroph cells. Cabergoline decreased serum prolactin levels in reserpinized rats.

Receptor-binding studies indicate low affinity for: dopamine D1-receptors, α1-adrenergic-receptors, α2-adrenergic-receptors.^[1]

Carcinogenity

In rodents a dose-dependent increase in malignant tumors has been found. The correlation is thought to be species specific. No clinical data exists on carcinogenity in humans.^{[citation needed]}

Uses

• Hyperprolactinemia.
• Adjunctive therapy of prolactin-producing pituitary gland tumors (prolactinomas).
• Monotherapy of Parkinson's disease in the early phase.
• Combination therapy, together with levodopa and a decarboxylase inhibitor such as carbidopa, in progressive-phase Parkinson's disease.
• In some countries also: ablactation and dysfunctions associated with hyperprolactinemia (amenorrhea, oligomenorrhea, anovulation, nonpuerperal mastitis and galactorrhea).
• Treatment of uterine fibroids.^[4][5]
• Adjunctive or second line therapy of acromegaly, cabergoline has low efficacy in suppressing growth hormone levels and is highly efficient in suppressing hyperprolactinemia that is present in 20-30% of acromegaly cases. Growth hormone and prolactin are similar structurally and have similar effects in many target tissues, therefore targeting prolactin may help symptoms when growth hormone secretion can not be sufficiently controlled by other methods.
• Cushing's disease - cabergoline may be used to lower ACTH levels and cause regression of ACTH producing pituitary adenomas.^[6]
• Other pituitary adenomas - cabergoline has demonstrated certain efficacy in controlling or reducing other kinds of pituitary adenomas, as well as silent or non-fucntional adenomas.

Off-label/recreational uses

It has at times been used as an adjunct to SSRI antidepressants as there is some evidence that it counteracts certain side effects of those drugs, such as reduced libido and anorgasmia. It also has been suggested online that it has a possible recreational use in reducing or eliminating the male refractory period. It is also used by bodybuilders to control gynecomastia caused by elevated prolactin levels through the use of anabolic steroids such as Nandrolone and Trenbolone. Additionally, a systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity, of ovarian hyperstimulation syndrome (OHSS), without compromising pregnancy outcomes, in females undergoing stimulated cycles of in vitro fertilization (IVF).^[7] Also, a study on rats found that cabergoline reduces voluntary alcohol consumption.^{[citation needed]}

Contraindications and precautions

• Hypersensitivity to ergot derivatives
• Pediatric patients (no clinical experience)
• Severely impaired liver function or cholestasis
• Co-medication with drugs metabolized mainly by CYP P450 such as erythromycin and ketoconazole, because increased plasma levels of cabergoline may result (although cabergoline undergoes minimal CYP450 metabolism).
• Cautions: severe cardiovascular disease, Raynaud's disease, gastroduodenal ulcers, active gastrointestinal bleeding, hypotension.

Pregnancy and lactation

Relatively little is known about the effects of this medication during pregnancy and lactation. In some cases the related bromocriptine may be an alternative when pregnancy is expected.^{[citation needed]}

• Pregnancy: available preliminary data indicates a somewhat increased rate of congenital abnormalities in patients who became pregnant while treated with cabergoline.^{[citation needed]}
• Lactation: In rats cabergoline was found in the maternal milk. Since it is not known if this effect also occurs in humans, breastfeeding is usually not recommended if treatment when treatment with cabergoline is necessary.
• Lactation suppression: In some countries cabergoline (Dostinex) is sometimes used as a lactation suppressant. It is also used in veterinary medicine to treat false pregnancy in dogs.

Side effects

Side effects are mostly dose dependent. Much more severe side effects are reported for treatment of Parkinson's disease and (off-label treatment) for restless leg syndrome which both typically require very high doses. The side effects are considered mild when used for treatment of hyperprolactinemia and other endocrine disorders or gynecologic indications where the typical dose is 10-100 times smaller than for Parkinson's disease.^{[citation needed]}

Cabergoline requires slow dose titration (2–4 weeks for hyperprolactinemia, often much longer for other conditions) to minimise side effects. The extremely long bioavailability of the medication may complicate dosing regimens during titration and require particular precautions.

Cabergoline is considered the best tolerable option for hyperprolactinemia treatment although the newer and less tested quinagolide may offer similarly favourable side effect profile with quicker titration times.

Approximately 200 patients with newly diagnosed Parkinson's disease participated in a clinical study of cabergoline monotherapy.^{[citation needed]} Seventy-nine (79) percent reported at least one side effect. These side effects were chiefly mild or moderate:

• GI tract: Side effects were extremely frequent. Fifty-three percent of patients reported side effects. Very frequent: Nausea (30%), constipation (22%), and dry mouth (10%). Frequent: Gastric irritation (7%), vomiting (5%), and dyspepsia (2%).
• Psychiatric disturbances and central nervous system (CNS): Altogether 51 percent of patients were affected. Very frequent: Sleep disturbances (somnolence 18%, insomnia 11%), vertigo (27%), and depression (13%). Frequent: dyskinesia (4%) and hallucinations (4%).
• Cardiovascular: Approximately 30 percent of patients experienced side effects. Most frequent were hypotension (10%), peripheral edema (14%) and non-specific edema (2%). Arrhythmias were encountered in 4.8%, palpitations in 4.3%, and angina pectoris in 1.4%.

In a combination study with 2,000 patients also treated with levodopa, the incidence and severity of side effects was comparable to monotherapy. Encountered side effects required a termination of cabergoline treatment in 15% of patients. Additional side effects were infrequent cases of hematological side effects, and an occasional increase in liver enzymes or serum creatinine without signs or symptoms.

As with other ergot derivatives, pleuritis, exudative pleura disease, pleura fibrosis, lung fibrosis, and pericarditis are seen. These side effects are noted in less than 2% of patients. They require immediate termination of treatment. Clinical improvement and normalization of X-ray findings are normally seen soon after cabergoline withdrawal. It appears that the dose typically used for treatment of hyperprolactinemia is too low to cause this type of side effects.

Valvular heart disease

In two studies published in the New England Journal of Medicine on January 4, 2007, cabergoline was implicated along with pergolide in causing valvular heart disease.^[8][9] As a result of this, the FDA removed pergolide from the U.S. market on March 29, 2007.^[10] Since cabergoline is not approved in the U.S. for Parkinson's Disease, but for hyperprolactinemia, the drug remains on the market. The lower doses required for treatment of hyperprolactinemia have been found to be not associated with clinically significant valvular heart disease or cardiac valve regurgitation.^[11][12]

Interactions

No interactions were noted with levodopa or selegiline. The drug should not be combined with other ergot derivatives. Dopamine antagonists such as antipsychotics and metoclopramide counteract some effects of cabergoline. The use of antihypertensive drugs should be intensively monitored because excessive hypotension may result from the combination.

Dosage

• Parkinson's disease: Monotherapy: Initial dose should be 0.5 mg daily. The usual maintenance dose is 2 to 4 mg daily. Combination therapy: Usually 2 to 6 mg daily.
• Tumors of the pituitary gland and other hyperprolactinemic conditions: Initially 0.5 mg per week, slowly titrated to 4.5 mg per week, if necessary.
• Ablactation: According to specific treatment scheme.

External links

• http://www.mayoclinic.com/health/drug-information/DR600285

References

1. ^ ^{a b} "Dostinex at www.rxlist.com". http://www.rxlist.com/cgi/generic/cabergoline.htm. Retrieved 2007-04-27. 
2. ^ US Patent 4526892 - Dimethylaminoalkyl-3-(ergoline-8'.beta.carbonyl)-ureas
3. ^ Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C (March 2009). "Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes". Experimental Eye Research 88 (3): 386–97. doi:10.1016/j.exer.2008.10.003. PMID 18992242. 
4. ^ Sayyah-Melli, M; Tehrani-Gadim, S; Dastranj-Tabrizi, A; Gatrehsamani, F; Morteza, G; Ouladesahebmadarek, E; Farzadi, L; Kazemi-Shishvan, M (2009). "Comparison of the effect of gonadotropin-releasing hormone agonist and dopamine receptor agonist on uterine myoma growth. Histologic, sonographic, and intra-operative changes". Saudi medical journal 30 (8): 1024–33. PMID 19668882.  edit
5. ^ Sankaran, S.; Manyonda, I. (2008). "Medical management of fibroids". Best Practice & Research Clinical Obstetrics & Gynaecology 22 (4): 655. doi:10.1016/j.bpobgyn.2008.03.001. PMID 18468953.  edit http://www.britishfibroidtrust.org.uk/journals/bft_Sankaran.pdf
6. ^ Miyoshi, T; Otsuka, F; Takeda, M; Inagaki, K; Suzuki, J; Ogura, T; Date, I; Hashimoto, K et al. (2004). "Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma". Journal of endocrinological investigation 27 (11): 1055–9. PMID 15754738.  edit
7. ^ Youssef MA, van Wely M, Hassan MA, et al. (March 2010). "Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis". Hum Reprod Update 16 (5): 459–66. doi:10.1093/humupd/dmq006. PMID 20354100. http://humupd.oxfordjournals.org/cgi/content/abstract/16/5/459?etoc. 
8. ^ Schade, Rene; Andersohn, Frank; Suissa, Samy; Haverkamp, Wilhelm; Garbe, Edeltraut (2007-01-04). "Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation". New England Journal of Medicine 356 (1): 29–38. doi:10.1056/NEJMoa062222. PMID 17202453. http://content.nejm.org/cgi/content/full/356/1/29 
9. ^ Zanettini, Renzo; Antonini, Angelo; Gatto, Gemma; Gentile, Rosa; Tesei, Silvana; Pezzoli, Gianna (2007-01-04). "Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease". New England Journal of Medicine 356 (1): 39–46. doi:10.1056/NEJMoa054830. PMID 17202454. http://content.nejm.org/cgi/content/full/356/1/39 
10. ^ "Food and Drug Administration Public Health Advisory". 2007-03-29. Archived from the original on 2007-04-08. http://web.archive.org/web/20070408111551/http://www.fda.gov/cder/drug/advisory/pergolide.htm. Retrieved 2007-04-27. 
11. ^ [1] Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
12. ^ [2] Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia